Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 199 results for biopsy

  1. Focal therapy using cryoablation for localised prostate cancer (HTG284)

    Evidence-based recommendations on focal therapy using cryoablation for localised stage prostate cancer. This involves using freezing (cryotherapy) needles to find and destroy only the cancerous part of the prostate.

  2. What is the natural history of people with a Likert score on MRI of less than 3 without biopsy at long-term follow‑up?

    natural history of people with a Likert score on MRI of less than 3 without biopsy at long-term follow‑up? Any explanatory notes(if...

  3. EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules (HTG611)

    Evidence-based recommendations on EarlyCDT Lung for assessing the risk of lung cancer in solid lung nodules.

  4. Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: the DYSIS colposcope with DYSISmap and the ZedScan I (HTG467)

    Evidence-based recommendations on 2 adjunctive colposcopy technologies (the DYSIS colposcope with DYSISmap and the ZedScan I) for assessing suspected cervical abnormalities in people having colposcopy.

  5. VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions (HTG388)

    Evidence-based recommendations on the VivaScope 1500 and 3000 imaging systems for detecting skin cancer lesions.

  6. Padeliporfin for untreated localised prostate cancer (TA546)

    Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults.

  7. High-intensity focused ultrasound for prostate cancer (HTG70)

    Evidence-based recommendations on high-intensity focused ultrasound for treating prostate cancer. This involves inserting a probe through the rectum that gives out a beam of ultrasound to heat and destroy the cancerous prostate tissue.

  8. Epithelial radiofrequency ablation for Barrett's oesophagus (HTG219)

    Evidence-based recommendations on epithelial radiofrequency ablation for Barrett's oesophagus. This involves using radiofrequency (heat) energy to destroy the abnormal cells and to promote the growth of healthy cells.

  9. superDimension Navigation System to help diagnostic sampling of peripheral lung lesions (MIB194)

    NICE has developed a medtech innovation briefing (MIB) on superDimension Navigation System to help diagnostic sampling of peripheral lung lesions .

  10. trublood-prostate for triaging and diagnosing people with prostate cancer symptoms (MIB268)

    NICE has developed a medtech innovation briefing (MIB) on trublood-prostate for triaging and diagnosing people with prostate cancer symptoms .

  11. Endoscopic radiofrequency ablation for Barrett's oesophagus with low‑grade dysplasia or no dysplasia (HTG345)

    Evidence-based recommendations on endoscopic radiofrequency ablation for Barrett’s oesophagus with low-grade dysplasia or no dysplasia. This involves using radiofrequency (heat) energy to destroy the abnormal cells and promote the growth of healthy normal cells.

  12. Endobronchial ultrasound-guided transbronchial needle aspiration for mediastinal masses (HTG163)

    Evidence-based recommendations on endobronchial ultrasound-guided transbronchial needle aspiration for mediastinal masses. This involves inserting a thin tube through the mouth into the lungs to take samples for examination.

  13. Stockholm3 for prostate cancer screening (MIB303)

    NICE has developed a medtech innovation briefing (MIB) on Stockholm3 for prostate cancer screening .

  14. Brain tumours (primary) and brain metastases in over 16s (NG99)

    This guideline covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in people aged 16 or over. It aims to improve diagnosis and care, including standardising the care people have, how information and support are provided, and palliative care.